Peptides that Increase the Efficacy of Monoclonal Antibody Therapy of Cancer

Focus: 

To validate the preclinical effectiveness and safety of a novel platform that enhances and enables the anti-tumor actions of therapeutic monoclonal antibodies

Anticipated Impact: 

Improved outcomes in cancer patients following treatment with monoclonal antibodies

Abstract: 

Monoclonal antibodies are used for the treatment of some cancers. Unfortunately, tumors can develop resistance to these therapies. The investigators have identified a method to enhance the sensitivity of cancer cells to monoclonal antibodies with no apparent toxic side effects. This study will expand preclinical efficacy and safety testing of combined monoclonal antibody therapy to support future clinical trials with cancer patients. A Washington-based emerging biotechnology company, Compliment Corp., has expressed interest in commercial development of the peptide.

Lymphoma Therapies

Grant Update

Principal Investigator:
Andre Lieber
Grantee Organization:
University of Washington
Grant Title:
Peptides that increase the efficacy of monoclonal antibody therapy of cancer
Grant Cohort and Year:
2009 Project Grant (01)
Grant Period:
01/26/2010 - 01/25/2012 (Completed)
Grant Amount:
$202,759
Collaborating Organizations:
Compliment Corp.
With the suppport of the LSDF grant we provided evidence in mice and non-human primates supporting the safety and efficacy of Ad35K++ in combination with rituximab in the therapy of hematologic malignancies. Ad35K++ co-therapy could potentially increase the therapeutic efficacy of rituximab and overcome resistance to treatment. Furthermore, Ad35K++ cotherapy could reduce the amounts of rituximab required for treatment, thus reducing its costs and potential side effects. Based on the encouraging results from these studies, we plan to advance this combination therapy into the clinic to treat patients with B-cell malignancies.

Impact in Washington

Location of LSDF Grantee
Locations of Collaborations/Areas of Impact
Seattle

Legislative Districts:
11, 34, 36, 37, 43, 46

Health Impacts

Lymphoma Therapies